Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

Published:2017-12-04 Issue:6 Volume:9 Page:6752-6762
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Boisen Mogens K.¹,Holst Camilla B.²,Consalvo Nicola³,Chinot Olivier L.⁴,Johansen Julia S.¹²⁵

Affiliation:

1. Department of Oncology, Herlev University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark

2. Department of Medicine, Herlev University Hospital, Herlev, and Gentofte Hospital, Copenhagen, Denmark

3. Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

4. Department of Neuro-Oncology, Aix-Marseille University, Marseille, France

5. Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors;Communications Medicine;2024-05-21

2. The evaluation of six genes combined value in glioma diagnosis and prognosis;Journal of Cancer Research and Clinical Oncology;2023-07-13

3. High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma;Cancers;2023-04-07

4. Biomarker analysis of VT1021, a first-in-class therapeutic agent that stimulates Thrombospondin-1 and reprograms the tumor microenvironment;2023-03-20

5. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults;Journal of Neuro-Oncology;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3